PEPTIDES
between T-EGF and hEGF (Figure 3). The transdermal efficacy of T-EGF in human skin was also
verified.The skin tissue was obtained from routine plastic surgeries performed at Hefei No.1 People’s Hospital. The patients signed informed consents to have their removed skin tissue collected for this research purpose. Following the careful removal of subcutaneous fat, the skin was placed in a Franz diffusion tank. The transdermal ability of T-EGF (50µg/mL) was monitored for 16 hours. The results indicated that, in human
skin, the transdermal efficiency of T-EGF is significantly higher than that of the control group (hEGF). Furthermore, it was observed that the skin permeation process of T-EGF is energy dependent. Upon addition of ATP, the transported T-EGF through skin barrier exhibited a substantial increase compared to the experimental group without ATP addition (Figure 4).
The repairing and moisturizing effect To substantiate the efficacy of T-EGF in terms of skin repair and moisturization, a comprehensive evaluation was conducted through a third-party commissioned institution (Report No. B136- 20230407-01-R1-V1, EviSkin). A cohort of 30 Asian individuals, exhibiting a baseline facial trans epidermal water loss (TEWL) value equal to or exceeding 16 g/m-h, were selected to participate in this investigation. T-EGF formulation at a concentration of 10µg/ml was used in this test. A significant reduction (p<0.05) in TEWL value post-application compared to pre-application indicated that the product possessed skin repair function. Additionally, data on the subjective
improvements of facial skin condition as well as the general skincare suitability was investigated
0.0% -5.0% -10.0% -15.0% * -20.0% After 28 days
Figure 5: Variations (versus baseline) in percentage on the mean of TEWL values. * indicates that the difference between the test value and the baseline value at this time point is statistically significant
TABLE 1: RESULT FOR IN VITRO SKIN IRRITATION BY RECONSTRUCTED HUMAN EPIDERMIS (%). TEST GROUP RESULT IS SIGNIFICANT COMPARED TO THE POSITIVE CONTROL. SDS = SODIUM DODECYL SULFATE
Group
Mean OD ± SD Viability ± SD (%) IL1a
(pg/ml)
Positive control (5 mg/ml SDS) Negative control (Ultra-pure grade water) 0.431 ± 0.009 41.596 ± 0.988 37.03 ± 4.51
1.059 ± 0.013 100 --
through a survey. An effectiveness rate equal to or surpassing 50% was regarded as indicative of a favourable outcome within the scope of the assessment parameters. The findings (Figure 5) revealed a statistically
significant reduction in the mean TEWL value following 28 days of employing the T-EGF samples in contrast to baseline value (P < 0.05). Following a 28-day application of T-EGF
Test group (T-EGF) 100µg/ml 1.036 ± 0.057 97.890 ± 5.376 8.646 ± 4.34
sample, all 30 participants reported notable improvements. One hundred percent of the subjects noted a reduction in facial skin dryness, with an equal percentage attesting to heightened facial skin hydration. Finally, the participants universally
experienced enhanced facial skin texture, improved facial skin tightness, and alleviation of sensations like burning, tingling, and redness, all
75
www.personalcaremagazine.com
November 2023 PERSONAL CARE
Mean variation in % (vs baseline)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
